Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae

Vaccine

Volumn 24, Issue 22, 2006, Pages 4804-4811

  Novotny, Laura A ^a   Jurcisek, Joseph A ^a   Godfroid, Fabrice ^b   Poolman, Jan T ^b   Denoël, Philippe A ^b   Bakaletz, Lauren O ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b GSK   (Belgium)

Author keywords

Conjugate vaccine; LPD; Polymicrobial disease; Superinfection

Indexed keywords

ANTISERUM; POLYSACCHARIDE PORTEIN D CONJUGATE VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CHINCHILLA; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HAEMOPHILUS INFLUENZAE; NONHUMAN; OTITIS MEDIA; PASSIVE IMMUNIZATION; PREDICTION; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT OUTCOME; VIRUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CARRIER PROTEINS; CHINCHILLA; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN D; LIPOPROTEINS; NASOPHARYNX; OTITIS MEDIA; POLYSACCHARIDES, BACTERIAL; VACCINES, CONJUGATE;

EID: 33646846479     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.021     Document Type: Article

References (57)

1. Bakaletz L.O. Developing animal models for polymicrobial diseases. Nat Rev Microbiol 2 7 (2004) 552-568
2. Bakaletz L.O. Otitis media. In: Brogden K.A., and Guthmiller J.M. (Eds). Polymicrobial diseases (2002), ASM Press, Washington, DC 259-298
3. Bakaletz L.O., Daniels R.L., and Lim D.J. Modeling adenovirus type 1-induced otitis media in the chinchilla: effect on ciliary activity and fluid transport function of Eustachian tube mucosal epithelium. J Infect Dis 168 4 (1993) 865-872
4. Suzuki K., and Bakaletz L.O. Synergistic effect of adenovirus type 1 and nontypeable Haemophilus influenzae in a chinchilla model of experimental otitis media. Infect Immun 62 5 (1994) 1710-1718
5. Bakaletz L.O. Viral potentiation of bacterial superinfection of the respiratory tract. Trends Microbiol 3 3 (1995) 110-114
6. Miyamoto N., and Bakaletz L.O. Kinetics of the ascension of NTHi from the nasopharynx to the middle ear coincident with adenovirus-induced compromise in the chinchilla. Microb Pathog 23 2 (1997) 119-126
7. Bakaletz L.O., Kennedy B.J., Novotny L.A., Duquesne G., Cohen J., and Lobet Y. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun 67 6 (1999) 2746-2762
8. Kennedy B.J., Novotny L.A., Jurcisek J.A., Lobet Y., and Bakaletz L.O. Passive transfer of antiserum specific for immunogens derived from a nontypeable Haemophilus influenzae adhesin and lipoprotein D prevents otitis media after heterologous challenge. Infect Immun 68 5 (2000) 2756-2765
9. Harrison A., Dyer D.W., Gillaspy A., Ray W.C., Mungur R., Carson M.B., et al. Genomic sequence of an otitis media isolate of nontypeable Haemophilus influenzae: comparative study with H. influenzae serotype d, strain KW20. J Bacteriol 187 13 (2005) 4627-4636
10. Teele D.W., Klein J.O., and Rosner B.A. Epidemiology of otitis media in children. Ann Otol Rhinol Laryngol Suppl 89 3 Pt 2 (1980) 5-6
11. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D provide protection against otitis media cause by both Streptococcus pneumoniae and nontypable Haemophilus influenzae. Lancet 367 (2006) 740-748
12. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Koi-Lommel I., et al. An eleven-valent pneumococcal-protein D conjugate (11pn-PD) vaccine protects against otitis caused by both pneumococci or Haemophilus influenzae. Proceedings of the 23rd annual meeting of the European society for paediatric infectious diseases, ESPID. Valencia, Spain (2005)
13. Bakaletz L.O., and Holmes K.A. Evidence for transudation of specific antibody into the middle ears of parenterally immunized chinchillas after an upper respiratory tract infection with adenovirus. Clin Diagn Lab Immunol 4 2 (1997) 223-225
14. Kyd J.M., Cripps A.W., Novotny L.A., and Bakaletz L.O. Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infect Immun 71 8 (2003) 4691-4699
15. Akkoyunlu M., Melhus A., Capiau C., van Opstal O., and Forsgren A. The acylated form of protein D of Haemophilus influenzae is more immunogenic than the nonacylated form and elicits an adjuvant effect when it is used as a carrier conjugated to polyribosyl ribitol phosphate. Infect Immun 65 12 (1997) 5010-5016
16. Akkoyunlu M., Janson H., Ruan M., and Forsgren A. Biological activity of serum antibodies to a nonacylated form of lipoprotein D of Haemophilus influenzae. Infect Immun 64 11 (1996) 4586-4592
17. Lees A., Nelson B.L., and Mond J.J. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14 3 (1996) 190-198
18. Nurkka A., Joensuu J., Henckaerts I., Peeters P., Poolman J., Kilpi T., et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr Infect Dis J 23 11 (2004) 1008-1014
19. Bakaletz L.O., Leake E.R., Billy J.M., and Kaumaya P.T. Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chinchilla. Vaccine 15 9 (1997) 955-961
20. Barenkamp S.J. Protection by serum antibodies in experimental nontypable Haemophilus influenzae otitis media. Infect Immun 52 2 (1986) 572-578
21. Sirakova T., Kolattukudy P.E., Murwin D., Billy J., Leake E., Lim D., et al. Role of fimbriae expressed by nontypeable Haemophilus influenzae in pathogenesis of and protection against otitis media and relatedness of the fimbrin subunit to outer membrane protein A. Infect Immun 62 5 (1994) 2002-2020
22. Giebink G.S., Heller K.A., and Harford E.R. Tympanometric configurations and middle ear findings in experimental otitis media. Ann Otol Rhinol Laryngol 91 1 Pt 1 (1982) 20-24
23. Margolis R.H., Hunter L.L., and Giebink G.S. Tympanometric evaluation of middle ear function in children with otitis media. Ann Otol Rhinol Laryngol Suppl 163 (1994) 34-38
24. Green B.A., Vazquez M.E., Zlotnick G.W., Quigley-Reape G., Swarts J.D., Green I., et al. Evaluation of mixtures of purified Haemophilus influenzae outer membrane proteins in protection against challenge with nontypeable H. influenzae in the chinchilla otitis media model. Infect Immun 61 5 (1993) 1950-1957
25. Tong H.H., Weiser J.N., James M.A., and DeMaria T.F. Effect of influenza A virus infection on nasopharyngeal colonization and otitis media induced by transparent or opaque phenotype variants of Streptococcus pneumoniae in the chinchilla model. Infect Immun 69 1 (2001) 602-606
26. Mason K.M., Munson Jr. R.S., and Bakaletz L.O. A mutation in the sap operon attenuates survival of nontypeable Haemophilus influenzae in a chinchilla model of otitis media. Infect Immun 73 1 (2005) 599-608
27. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000) 187-195
28. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362 9381 (2003) 355-361
29. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., and Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 14 (2003) 1341-1348
30. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344 6 (2001) 403-409
31. Obaro S.K., Adegbola R.A., Banya W.A., and Greenwood B.M. Carriage of pneumococci after pneumococcal vaccination. Lancet 348 9022 (1996) 271-272
32. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., and Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 180 4 (1999) 1171-1176
33. Veenhoven R., Bogaert D., Uiterwaal C., Brouwer C., Kiezebrink H., Bruin J., et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 361 9376 (2003) 2189-2195
34. McEllistrem M.C., Adams J., Mason E.O., and Wald E.R. Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis 188 11 (2003) 1679-1684
35. Pelton S.I., Loughlin A.M., and Marchant C.D. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 23 11 (2004) 1015-1022
36. Kilpi T., Ahman H., Jokinen J., Lankinen K.S., Palmu A., Savolainen H., et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 37 9 (2003) 1155-1164
37. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 9465 (2005) 1139-1146
38. Dagan R. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Curr Opin Otolaryngol Head Neck Surg 12 6 (2004) 488-494
39. Giebink G.S. Otitis media: the chinchilla model. Microb Drug Resist 5 1 (1999) 57-72
40. Giebink G.S., Berzins I.K., Marker S.C., and Schiffman G. Experimental otitis media after nasal inoculation of Streptococcus pneumoniae and influenza A virus in chinchillas. Infect Immun 30 2 (1980) 445-450
41. Giebink G.S., and Wright P.F. Different virulence of influenza A virus strains and susceptibility to pneumococcal otitis media in chinchillas. Infect Immun 41 3 (1983) 913-920
42. Giebink G.S. Studies of Streptococcus pneumoniae and influenza virus vaccines in the chinchilla otitis media model. Pediatr Infect Dis J 8 Suppl 1 (1989) S42-S44
43. Giebink G.S., Koskela M., Vella P.P., Harris M., and Le C.T. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 167 2 (1993) 347-355
44. Karma P.H., Bakaletz L.O., Giebink G.S., Mogi G., and Rynnel-Dagoo B. Immunological aspects of otitis media: present views on possibilities of immunoprophylaxis of acute otitis media in infants and children. Int J Pediatr Otorhinolaryngol 32 Suppl (1995) S127-S134
45. Giebink G.S., Meier J.D., Quartey M.K., Liebeler C.L., and Le C.T. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model. J Infect Dis 173 1 (1996) 119-127
46. Whitby P.W., Sim K.E., Morton D.J., Patel J.A., and Stull T.L. Transcription of genes encoding iron and heme acquisition proteins of Haemophilus influenzae during acute otitis media. Infect Immun 65 11 (1997) 4696-4700
47. Gray-Owen S.D., and Schryvers A.B. Characterization of transferrin binding proteins 1 and 2 in invasive type b and nontypeable strains of Haemophilus influenzae. Infect Immun 63 10 (1995) 3809-3815
48. Cope L.D., Hrkal Z., and Hansen E.J. Detection of phase variation in expression of proteins involved in hemoglobin and hemoglobin-haptoglobin binding by nontypeable Haemophilus influenzae. Infect Immun 68 7 (2000) 4092-4101
49. Denoel P.A., Godfroid F., Thonnard J., Neyt C., Dyer D.W., and Poolman J.T. Moraxella catarrhalis and nontypeable Haemophilus influenzae vaccine to prevent otitis media. In: Levine M., Kaper J.B., Rappuoli R., Liu M.A., and Good M.F. (Eds). New generation vaccines, third edition, revised and expanded (2004), Marcel Dekker, Inc., New York 817-834
50. Bakaletz L.O., Baker B.D., Jurcisek J.A., Harrison A., Novotny L.A., Bookwalter J.E., et al. Demonstration of Type IV pilus expression and a twitching phenotype by Haemophilus influenzae. Infect Immun 73 3 (2005) 1635-1643
51. St Geme III J.W. Insights into the mechanism of respiratory tract colonization by nontypable Haemophilus influenzae. Pediatr Infect Dis J 16 10 (1997) 931-935
52. Loosmore S.M., Yang Y.P., Coleman D.C., Shortreed J.M., England D.M., and Klein M.H. Outer membrane protein D15 is conserved among Haemophilus influenzae species and may represent a universal protective antigen against invasive disease. Infect Immun 65 9 (1997) 3701-3707
53. Webb D.C., and Cripps A.W. Immunization with recombinant transferrin binding protein B enhances clearance of nontypeable Haemophilus influenzae from the rat lung. Infect Immun 67 5 (1999) 2138-2144
54. Kyd J.M., Dunkley M.L., and Cripps A.W. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 63 8 (1995) 2931-2940
55. Sun J., Chen J., Cheng Z., Robbins J.B., Battey J.F., and Gu X.X. Biological activities of antibodies elicited by lipooligosaccharide based-conjugate vaccines of nontypeable Haemophilus influenzae in an otitis media model. Vaccine 18 13 (2000) 1264-1272
56. Wu T.H., and Gu X.X. Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae. Infect Immun 67 10 (1999) 5508-5513
57. Gu X.X., Sun J., Jin S., Barenkamp S.J., Lim D.J., Robbins J.B., et al. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas. Infect Immun 65 11 (1997) 4488-4493